Show simple item record

Article

dc.creatorHontecillas Prieto, Lourdeses
dc.creatorGarcía-Domínguez, Daniel J.es
dc.creatorPascual Vaca, Diegoes
dc.creatorGarcía Mejías, Rosaes
dc.creatorMarcilla, Davides
dc.creatorRamírez Villar, Gemaes
dc.creatorÁlava Casado, Enrique dees
dc.date.accessioned2020-05-18T10:22:02Z
dc.date.available2020-05-18T10:22:02Z
dc.date.issued2017
dc.identifier.citationHontecillas Prieto, L., García Dominguez, D., Pascual Vaca, D., García Mejías, R., Marcilla, D., Ramírez Villar, G. y Alava, E.d. (2017). Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients. Oncotarget, 8 (7), 1-14.
dc.identifier.issn1949-2553es
dc.identifier.urihttps://hdl.handle.net/11441/96823
dc.description.abstractWilms tumour (WT) is the most common renal tumour in children. Most WT patients respond to chemotherapy, but subsets of tumours develop resistance to chemotherapeutic agents, which is a major obstacle in their successful treatment. Multidrug resistance transporters play a crucial role in the development of resistance in cancer due to the efflux of anticancer agents out of cells. The aim of this study was to explore several human multidrug resistance transporters in 46 WT and 40 nonneoplastic control tissues (normal kidney) from patients selected after chemotherapy treatment SIOP 93–01, SIOP 2001. Our data showed that the majority of the studied multidrug resistance transporters were downregulated or unchanged between tumours and control tissues. However, BCRP1, MDR3 and MRP1 were upregulated in tumours versus control tissues. MDR3 and MRP1 overexpression correlated with highrisk tumours (SIOP classification) (p = 0.0022 and p < 0.0001, respectively) and the time of disease-free survival was significantly shorter in patients with high transcript levels of MDR3 (p = 0.0359). MDR3 and MRP1 play a role in drug resistance in WT treatment, probably by alteration of an unspecific drug excretion system. Besides, within the blastemal subtype, we observed patients with low MDR3 expression were significantly associated with a better outcome than patients with high MDR3 expression. We could define two types of blastemal WT associated with different disease outcomes, enabling the stratification of blastemal WT patients based on the expression levels of the multidrug resistance transporter MDR3.es
dc.description.sponsorshipMinisterio de Economía y Competitividad PI1401466, RD06/0020/0059, PI1100018, CD06/00001es
dc.description.sponsorshipRed Tematica de Investigacion Cooperativa en Cancer RD12/0036/0017es
dc.description.sponsorshipUnión Europea FP7-HEALTH- 2011-two-stage, Project ID 278742 EUROSARCes
dc.description.sponsorshipInstituto de Salud Carlos III FIS PI13/02282es
dc.formatapplication/pdfes
dc.format.extent14es
dc.language.isoenges
dc.publisherImpact Journalses
dc.relation.ispartofOncotarget, 8 (7), 1-14.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectWilms tumourses
dc.subjectMultidrug resistance transporterses
dc.subjectMDR3es
dc.subjectMRP1es
dc.subjectBlastemal stratificationes
dc.titleMultidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patientses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationInstituto de Biomedicina de Sevilla (IBIS)es
dc.identifier.doi108632/oncotarget 14491es
dc.journaltitleOncotargetes
dc.publication.volumen8es
dc.publication.issue7es
dc.publication.initialPage1es
dc.publication.endPage14es

FilesSizeFormatViewDescription
Multidrug resistance transporter ...3.585MbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional